Genes and proteins differentially expressed during in vitro malignant transformation of bovine pancreatic duct cells

Neoplasia

Volumn 9, Issue 2, 2007, Pages 136-146

  Jesnowski, R ^a,b   Zubakov, Dmitri ^a   Faissner, Ralf ^a,b   Ringel, Jörg ^a,b   Hoheisel, Jörg D ^a   Lösel, Ralf ^b   Schnölzer, Martina ^a   Löhr, Matthias ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ki ras; Pancreatic carcinogenesis; Proteomics; SV40 large T; Transcriptomics

Indexed keywords

RAS PROTEIN; RNA;

ANIMAL CELL; ARTICLE; BBC1 GENE; CARCINOGENESIS; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; EXPRESSED SEQUENCE TAG; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GLTSCR2 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREAS CELL; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLE; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 33847300960     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06754     Document Type: Article

References (82)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, and Thun MJ (2006). Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
2. Freelove R and Walling AD (2006). Pancreatic cancer: diagnosis and management. Am Fam Phys 73, 485-492.
3. Morohoshi T, Held G, and Klöppel G (1983). Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology 7, 645-661.
4. Grapin-Botton A (2005). Ductal cells of the pancreas. Int J Biochem Cell Biol 37, 504-510.
5. Löhr M, Klöppel G, Maisonneuve P, Lowenfels AB, and Lüttges J (2005). Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 7, 17-23.
6. Löhr M, Müller P, Zauner I, Schmidt C, Trautmann B, Thevenod F, Capella G, Farre A, Liebe S, and Jesnowski R (2001). Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras. Virchows Arch 438, 581-590.
7. Diehl F, Grahlmann S, Beier M, and Hoheisel JD (2001). Manufacturing DNA microarrays of high spot homogeneity and reduced background signal. Nucleic Acids Res 29, E38.
8. Fielden MR, Halgren RG, Dere E, and Zacharewski TR (2002). GP3: GenePix post-processing program for automated analysis of raw microarray data. Bioinformatics 18, 771-773.
9. Mortz E, Krogh TN, Vorum H, and Gorg A (2001). Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis. Proteomics 1, 1359-1363.
10. Bardeesy N and DePinho RA (2002). Pancreatic cancer biology and genetics. Nat Rev Cancer 2, 897-909.
11. Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-Olson JF, Korc M, Hammer J, and Büchler MW (2003). Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 60, 1180-1199.
12. Iacobuzio-Donahue CA and Hruban RH (2003). Gene expression in neoplasms of the pancreas: applications to diagnostic pathology. Adv Anat Pathol 10, 125-134.
13. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A, and Lemoine NR (2002). Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21, 4587-4594.
14. Grützmann R, Foerder M, Alldinger I, Staub E, Brummendorf T, Ropcke S, Li X, Kristiansen G, Jesnowski R, Sipos B, et al. (2003). Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch 443, 508-517.
15. Brandt R, Grützmann R, Bauer A, Jesnowski R, Ringel J, Löhr M, Pilarsky C, and Hoheisel JD (2004). DNA microarray analysis of pancreatic malignancies. Pancreatology 4, 587-597.
16. Grützmann R, Boriss H, Ammerpohl O, Lüttges J, Kalthoff H, Schackert HK, Klöppel G, Saeger HD, and Pilarsky C (2005). Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24, 5079-5088.
17. Gygi SP, Rochon Y, Franza BR, and Aebersold R (1999). Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19, 1720-1730.
18. Chen R, Yi EC, Donohoe S, Pan S, Eng J, Cooke K, Crispin DA, Lane Z, Goodlett DR, Bronner MP, et al. (2005). Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129, 1187-1197.
19. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, et al. (2005). Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129, 1454-1463.
20. Löhr JM, Faissner R, Findeisen P, and Neumaier M (2006). Proteome analysis - basis for individualized pancreatic carcinoma therapy? Internist (Berlin) 47 (1), S40-S48.
21. Ohnami S, Matsumoto N, Nakano M, Aoki K, Nagasaki K, Sugimura T, Terada M, and Yoshida T (1999). Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity. Cancer Res 59, 5565-5571.
22. Qian J, Niu J, Li M, Chiao PJ, and Tsao MS (2005). In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res 65, 5045-5053.
23. Shen J, Person MD, Zhu J, Abbruzzese JL, and Li D (2004). Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64, 9018-9026.
24. Yamazaki D, Kurisu S, and Takenawa T (2005). Regulation of cancer cell motility through actin reorganization. Cancer Sci 96, 379-386.
25. Kaneko K, Satoh K, Masamune A, Satoh A, and Shimosegawa T (2002). Myosin light chain kinase inhibitors can block invasion and adhesion of human pancreatic cancer cell lines. Pancreas 24, 34-41.
26. Rao L, Perez D, and White E (1996). Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol 135, 1441-1455.
27. Ku NO, Liao J, and Omary MB (1997). Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272, 33197-33203.
28. Byun Y, Chen F, Chang R, Trivedi M, Green KJ, and Cryns VL (2001). Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 8, 443-450.
29. Chan R, Rossitto PV, Edwards BF, and Cardiff RD (1986). Presence of proteolytically processed keratins in the culture medium of MCF-7 cells. Cancer Res 46, 6353-6359.
30. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, and Michel FB (1993). Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53, 61-66.
31. Sheard MA, Vojtesek B, Simickova M, and Valik D (2002). Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 85, 670-677.
32. Asumendi A, Andollo N, Boyano MD, Hilario E, Perez-Yarza G, Atencia R, Arechaga J, and Garcia-Sanz M (2000). The role of cleavage of cell structures during apoptosis. Cell Mol Biol (Noisy-le-Grand) 46, 1-11.
33. Lavastre V, Chiasson S, Cavalli H, and Girard D (2005). Viscum album agglutinin-I induces apoptosis and degradation of cytoskeletal proteins via caspases in human leukaemia eosinophil AML14.3D10 cells: differences with purified human eosinophils. Br J Haematol 130, 527-535.
34. Lindquist S and Craig EA (1988). The heat-shock proteins. Annu Rev Genet 22, 631-677.
35. Odunuga OO, Longshaw VM, and Blatch GL (2004). Hop: more than an Hsp70/Hsp90 adaptor protein. Bioessays 26, 1058-1068.
36. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, and Kroemer G (2006). Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5, 2592-2601.
37. Tauchi K, Tsutsumi Y, Hori S, Yoshimura S, Osamura RY, and Watanabe K (1991). Expression of heat shock protein 70 and c-myc protein in human breast cancer: an immunohistochemical study. Jpn J Clin Oncol 21, 256-263.
38. Liu X, Ye L, Wang J, and Fan D (1999). Expression of heat shock protein 90 beta in human gastric cancer tissue and SGC7901/VCR of MDR-type gastric cancer cell line. Chin Med J (Engl) 112, 1133-1137.
39. Kanazawa Y, Isomoto H, Oka M, Yano Y, Soda H, Shikuwa S, Takeshima F, Omagari K, Mizuta Y, Murase K, et al. (2003). Expression of heat shock protein (Hsp) 70 and Hsp 40 in colorectal cancer. Med Oncol 20, 157-164.
40. Ogata M, Naito Z, Tanaka S, Moriyama Y, and Asano G (2000). Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 67, 177-185.
41. Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, and Fuqua SA (1997). The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis 17, 113-123.
42. Jaattela M (1995). Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. Int J Cancer 60, 689-693.
43. Steiner K, Graf M, Hecht K, Reif S, Rossbacher L, Pfister K, Kolb HJ, Schmetzer HM, and Multhoff G (2006). High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis. Leukemia 20, 2076-2079.
44. Miyazaki T, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, Masuda N, Manda R, Fukuchi M, Ojima H, et al. (2005). Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res 25, 2749-2755.
45. Wang XP, Qiu FR, Liu GZ, and Chen RF (2005). Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol 11, 1056-1059.
46. Sagol O, Tuna B, Coker A, Karademir S, Obuz F, Astarcioglu H, Kupelioglu A, Astarcioglu I, and Topalak O (2002). Immunohistochemical detection of pS2 protein and heat shock protein-70 in pancreatic adenocarcinomas. Relationship with disease extent and patient survival. Pathol Res Pract 198, 77-84.
47. Antoniou AN, Ford S, Alphey M, Osborne A, Elliott T, and Powis SJ (2002). The oxidoreductase ERp57 efficiently reduces partially folded in preference to fully folded MHC class I molecules. EMBO J 21, 2655-2663.
48. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, and Schrump DS (2002). Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94, 504-513 (April 3).
49. Hirano N, Shibasaki F, Sakai R, Tanaka T, Nishida J, Yazaki Y, Takenawa T, and Hirai H (1995). Molecular cloning of the human glucose-regulated protein ERp57/GRP58, a thiol-dependent reductase. Identification of its secretory form and inducible expression by the oncogenic transformation. Eur J Biochem 234, 336-342.
50. Nakatani K, Nakamura M, Uzawa K, Wada T, Seki N, Tanzawa H, and Fujita S (2005). Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. Oncol Rep 13, 709-714.
51. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, et al. (2005). High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7, 603-613.
52. Su S, Adikesavan AK, and Jaiswal AK (2006). si RNA inhibition of GRP58 associated with decrease in mitomycin C-induced DNA cross-linking and cytotoxicity. Chem Biol Interact 162, 81-87.
53. Okahara F, Ikawa H, Kanaho Y, and Maehama T (2004). Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem 279, 45300-45303.
54. Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, Halachmi N, Ahrendt SA, Reed AL, Hilgers W, et al. (1998). Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 58, 509-511.
55. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, and Reddy SA (2004). The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23, 8571-8580.
56. Adams SM, Helps NR, Sharp MG, Brammar WJ, Walker RA, and Varley JM (1992). Isolation and characterization of a novel gene with differential expression in benign and malignant human breast tumours. Hum Mol Genet 1, 91-96.
57. Schmutzler RK, Fimmers R, Bierhoff E, Lohmar B, Homann A, Speiser P, Kubista E, Jaeger K, Krebs D, Zeillinger R, et al. (1996). Association of allelic losses on human chromosomal arms 11Q and 16Q in sporadic breast cancer. Int J Cancer 69, 307-311.
58. Moerland E, Breuning MH, Cornelisse CJ, and Cleton-Jansen AM (1997). Exclusion of BBC1 and CMAR as candidate breast tumour-suppressor genes. Br J Cancer 76, 1550-1553.
59. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, and Kallioniemi OP (1995). Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55, 342-347.
60. Hugel A and Wernert N (1999). Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. Br J Cancer 79, 551-557.
61. Chang MC, Chang YT, Tien YW, Sun CT, Wu MS, and Lin JT (2005). Distinct chromosomal aberrations of ampulla of Vater and pancreatic head cancers detected by laser capture microdissection and comparative genomic hybridization. Oncol Rep 14, 867-872.
62. Olofsson B (1999). Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 11, 545-554.
63. Erickson JW and Cerione RA (2001). Multiple roles for Cdc42 in cell regulation. Curr Opin Cell Biol 13, 153-157.
64. Fukumoto Y, Kaibuchi K, Hori Y, Fujioka H, Araki S, Ueda T, Kikuchi A, and Takai Y (1990). Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins. Oncogene 5, 1321-1328.
65. Lin Q, Fuji RN, Yang W, and Cerione RA (2003). RhoGDI is required for Cdc42-mediated cellular transformation. Curr Biol 13, 1469-1479.
66. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF III (2002). Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76-84.
67. Fritz G, Brachetti C, Bahlmann F, Schmidt M, and Kaina B (2002). Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87, 635-644.
68. MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, and Ting JP (2003). Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 63, 6928-6934.
69. Lu Z, Hu L, Evers S, Chen J, and Shen Y (2004). Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics 4, 3975-3988.
70. Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, and Kikuchi Y (2006). Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol Rep 15, 1265-1271.
71. Zhang B, Zhang Y, Dagher MC, and Shacter E (2005). Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 65, 6054-6062.
72. Poland J, Sinha P, Siegert A, Schnolzer M, Korf U, and Hauptmann S (2002). Comparison of protein expression profiles between monolayer and spheroid cell culture of HT-29 cells revealed fragmentation of CK18 in three-dimensional cell culture. Electrophoresis 23, 1174-1184.
73. Raynal P and Pollard HB (1994). Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1197, 63-93.
74. Kamal AM, Flower RJ, and Perretti M (2005). An overview of the effects of annexin 1 on cells involved in the inflammatory process. Mem Inst Oswaldo Cruz 100 (1), 39-47.
75. Perretti M and D'Acquisto F (2006). Novel aspects of annexin 1 and glucocorticoid biology: intersection with nitric oxide and the lipoxin receptor. Curr Drug Targets (Inflamm Allergy) 5, 107-114.
76. Ahn SH, Sawada H, Ro JY, and Nicolson GL (1997). Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis 15, 151-156.
77. Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, Itano T, Matsui H, Arima K, Shirai M, et al. (1996). Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 24, 72-81.
78. Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, et al. (2000). Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 60, 6293-6297.
79. Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS, Wang K, et al. (2004). Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol 10, 1466-1470.
80. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, and Lage H (1998). Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods 37, 105-116.
81. Carollo M, Parente L, and D'Alessandro N (1998). Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1. Oncol Res 10, 245-254.
82. Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM, and Georges E (2004). Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun 314, 565-570.